Arcutis Biotherapeutics Inc. (ARQT): Price and Financial Metrics
GET POWR RATINGS... FREE!
ARQT Stock Price Chart Interactive Chart >
ARQT Price/Volume Stats
|Current price||$20.99||52-week high||$29.37|
|Prev. close||$19.66||52-week low||$13.59|
|Day high||$21.31||Avg. volume||286,520|
|50-day MA||$19.71||Dividend yield||N/A|
|200-day MA||$19.31||Market Cap||1.08B|
Arcutis Biotherapeutics Inc. (ARQT) Company Bio
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.
Most Popular Stories View All
ARQT Latest News Stream
|Loading, please wait...|
ARQT Latest Social Stream
View Full ARQT Social Stream
Latest ARQT News From Around the Web
Below are the latest news stories about Arcutis Biotherapeutics Inc that investors may wish to consider to help them evaluate ARQT as an investment opportunity.
Received U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for roflumilast cream for the treatment of plaque psoriasis in adults and adolescentsCompleted enrollment of the sole pivotal Phase 3 trial of roflumilast foam in seborrheic dermatitisEnrolling pivotal Phase 3 trials of roflumilast cream in atopic dermatitis and roflumilast foam in scalp and body psoriasisSecured $225 million in non-dilutive debt financing from SLR Capital Partners, further strengthenin
In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on Arcutis Biotherapeutics (ARQT – Research Report), with a price target of $58.00. The company's shares closed last Tuesday at $15.61, close to its 52-week low of $13.59. According to TipRanks.com, Ear 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -14.6% and a 36.4% success rate. Ear covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, uniQure, and Avrobio. Currently, the analyst consensus on Arcutis Biotherapeutics is a Moderate Buy with an average price target of $46.50.
Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals with Seborrheic Dermatitis
Topline data now anticipated in mid-year 2022, followed by a regulatory submission in first half of 2023A total of 457 subjects are enrolled in the STRATUM studySeborrheic dermatitis affects 10 million people in the U.S. WESTLAKE VILLAGE, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the enrollment of the last subject in its STRATUM
Mizuho Securities analyst Uy Ear reiterated a Buy rating on Arcutis Biotherapeutics (ARQT – Research Report) today and set a price target of $58.00. The company's shares closed last Friday at $17.41, close to its 52-week low of $14.16. According to TipRanks.com, Ear is a 1-star analyst with an average return of -11.2% and a 28.6% success rate. Ear covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Avrobio, and uniQure. Arcutis Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $46.50. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $38.49 and a one-year low of $14.16.
In this article, we discuss the 10 small-cap stocks to buy according to billionaire Steve Cohen. You can skip our detailed analysis of Steve Cohen’s hedge fund, and go directly to read 5 Small-Cap Stocks to Buy According to Billionaire Steve Cohen. Billionaire investor Steve Cohen is the brain behind Point72 Asset Management, a hedge fund […]
ARQT Price Returns